Please assess the completion status of the following clinical trial:

Trial Title: Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must have a histologically or cytologically confirmed diagnosis of: Acute Myelogenous Leukemia Myelodysplastic Syndrome Acute Lymphocytic Leukemia Lymphoma (Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma)~2. Must be \> 18 years of age~3. Subject is likely to benefit from allogeneic transplant in the opinion of the transplant physician~4. An human leukocyte antigen (HLA)-identical related or unrelated donor cannot be identified within an appropriate time frame~5. Karnofsky Performance Status (KPS) of \> 80~6. Subject has acceptable organ and marrow function as defined below: Serum bilirubin \< 2.0mg/dL ALT(SGPT) 3 X upper limit of normal Creatinine Clearance \> 50 mL/min as estimated by the modified MDRD equation.18~7. Ability to understand and the willingness to sign a written informed consent document.~8. A preliminary search has identified both:~   1. Appropriate umbilical cords for a single, or if necessary a double umbilical cord blood (UCB) transplant AND~  2. An appropriate single UCB as well as an appropriate haplo donor for haplo-cord transplant~Exclusion Criteria:~1. Myeloproliferative disorders, hemoglobinopathies, severe aplastic anemia or any diagnosis not listed under 3.1.1~2. Life expectancy is severely limited by concomitant illness or uncontrolled infection~3. Subjects with severely decreased Left Ventricular Ejection Fraction (LVEF) or impaired pulmonary function tests (PFTs)~4. Subject has evidence of chronic active hepatitis or cirrhosis~5. Subject is HIV-positive~6. Subject is pregnant or lactating. -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Haplo-Cord SCT (Type: EXPERIMENTAL): The UCB unit must supply a minimum of 1.0 x107/kg pre-cryopreserved nucleated cell dose. The unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
- UCB SCT (Type: ACTIVE_COMPARATOR): For the standard arm, UCB units will be selected using the Minnesota strategy and the strategy followed in a recent CTN study.17;19Each unit must supply a minimum of 1.5 x107/kg pre-cryopreserved nucleated cell dose. Subjects must have two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1

Based on this trial design, predict the completion outcome and termination type (if applicable).